Last reviewed: May 23, 2026 Last updated: May 23, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
1989 Jan;96(1):79-85
Purpose: First meaningful escalation
Different diabetes medications demonstrate varying effects on cancer risk, with some showing protective effects while others may potentially increase risk in certain populations [10, 13, 14]
General age eligibility is 1874 (Nebraska requires 19+)
GLP-1 drugs also reduced related hospital admissions by 26% versus the SGLT-2s, related deaths by 50%, drug overdoses by 39%, and suicidal ideation or attempt by 25%